

PHYSICIAN ORDER SET :  
**FERUMOXYTOL**

CDH 208-253 – Approved - Page 1 of 3

Patient: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender: \_\_\_\_\_  
 Patient Phone #: \_\_\_\_\_ Height: \_\_\_\_\_ Weight: \_\_\_\_\_  
 Diagnosis: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_  
 Treatment Start Date: \_\_\_\_\_  
 Provider Facility Name: \_\_\_\_\_ Provider Facility Address: \_\_\_\_\_  
 Ordering Provider: \_\_\_\_\_ Date: \_\_\_\_\_  
 Signature: \_\_\_\_\_

**Communication Orders**
☐ **Provider and Nurse Communication**

Interval	Defer Until	Duration
1 time a week		1 treatment

Routine  
 Do NOT administer to patient who is expected to require and MRI within the next 3 months.

**Medications**
☐ **ferumoxytol (FERAHEME) IVPB 510 mg of elem iron**

Interval	Defer Until	Duration
1 time a week, at least 3 days apart		2 treatments

510 mg of elem iron, Intravenous, Administer over 15 minutes, Once Starting at treatment start time, For 1 dose  
 Expressed in terms of elemental iron.

**Catheter Management**
☐ **Line Access**

Interval	Defer Until	Duration
PRN		PRN

Routine, As needed, Starting when released, Until Specified.  
 As needed. Until Specified. Insert peripheral IV, or access peripheral, or central venous access device to provide treatment.

☐ **alteplase (CATHFLO) 1mg/mL injection 2 mg**

Interval	Defer Until	Duration
PRN		PRN

2 mg, Intracatheter, As needed, line care, Starting when released. For central venous access device requiring clearance. May repeat once per lumen.  
 For patients greater than 30 kg: 2 mg in 2 mL using a 10 mL syringe.  
 For patient less than or equal to 30 kg: instill a volume equal to 110% of the internal lumen of CVAD, not to exceed 2 mg in 2 mL.

PHYSICIAN ORDER SET :  
**FERUMOXYTOL**

CDH 208-253 – Approved - Page 2 of 3

<input type="checkbox"/>	<b>lidocaine-prilocaine (EMLA) cream</b> Topical, As needed, apply prior to the PIV insertion or port access, Starting when released. For TOPICAL Use only. Allow at least 1 hour (mild dermal procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect.	PRN	PRN
<input type="checkbox"/>	<b>heparin (PF) 100 unit/mL flush 5 mL</b> 5 mL, Intravenous, As needed, line care, Starting when released	PRN	PRN
<input type="checkbox"/>	<b>heparin (PF) 10 unit/mL flush 3 mL</b> 3 mL, Intravenous, As needed, line care, Starting when released	PRN	PRN
<input type="checkbox"/>	<b>heparin (PF) 10 unit/mL flush 5 mL</b> 5 mL, Intravenous, As needed, line care, Starting when released	PRN	PRN
<input type="checkbox"/>	<b>heparin (PF) 1000 unit/mL catheter injection 2 mL</b> 2 mL, Intracatheter, As needed, APHERESIS LINE CARE ONLY. HEPARIN MUST BE WITHDRAWN FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHERESIS CATHETER, Starting when released	PRN	PRN
<input type="checkbox"/>	<b>sodium chloride (NS) 0.9% syringe flush 3 mL</b> 3 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN	PRN
<input type="checkbox"/>	<b>sodium chloride (NS) 0.9% syringe flush 10 mL</b> 10 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN	PRN
<input type="checkbox"/>	<b>sodium chloride (NS) 0.9% syringe flush 20 mL</b> 20 mL, Intravenous, As needed, Line care per institutional guidelines, Starting when released.	PRN	PRN
<input type="checkbox"/>	<b>sodium chloride 0.9% infusion</b> 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide treatment, Starting when released	PRN	PRN
<input type="checkbox"/>	<b>D5W infusion</b> 20 mL/hr, Intravenous, Continuous PRN, Keep vein open to provide treatment, Starting when released, For 24 hours	PRN	PRN

**Emergency Medications/Anaphylaxis**

	Interval	Defer Until	Duration
<input type="checkbox"/>	PRN		PRN
<b>Provider and Nurse Communication</b> Routine, Once, Starting when released. Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wheezing, respiratory distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY medications as clinically indicated.			
<input type="checkbox"/>	PRN		PRN
<b>EPINEPHrine (ADRENALIN) injection 0.3 mg</b> 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis. May repeat times 1 dose, Starting when released For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 equivalent to 1 mg/mL			
<input type="checkbox"/>	PRN		PRN
<b>sodium chloride 0.9% bolus 1,000 mL</b> 1,000 mL, Intravenous, Once as needed, Hypotension, Starting when released, For 1 dose			
<input type="checkbox"/>	PRN		PRN
<b>Oxygen Therapy – Non-Rebreather</b> Routine Select a Mode of Therapy: Non-Rebreather Titrate Oxygen and use the most appropriate device to maintain Target Oxygen saturation during Activity/Titration: Yes Min SpO2 (%): 94			

PHYSICIAN ORDER SET :  
**FERUMOXYTOL**

CDH 208-253 – Approved - Page 3 of 3

**Hypersensitivity**

	Interval	Defer Until	Duration
<input type="checkbox"/> <b>Provider and Nurse Communication</b> Routine, Until discontinued, Starting when released. Until Specified. Treatment for mild-moderate infusion reaction: Stop the infusion, notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering medications as clinically indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section.	PRN		Until discontin'td
<input type="checkbox"/> <b>albuterol 2.5mg/3 mL (0.83%) nebulizer solution</b> 2.5 mg, Nebulization, Once as needed, wheezing, shortness of breath, Starting when released, For 1 dose	PRN		Until discontin'td
<input type="checkbox"/> <b>acetaminophen (TYLENOL) tablet 975</b> 975 mg, Oral, Once as needed, fever, Starting at treatment start time, For 1 dose	PRN		Until discontin'td
<input type="checkbox"/> <b>diphenhydramine (BENADRYL) injection 25 mg</b> 25 mg, Intravenous, As needed, itching, hives or adjunct treatment for mild-moderate, or SEVERE reaction, Starting when released, For 2 doses. Begin with 25 mg. If patient has continue reaction, administer additional 25 mg	PRN		Until discontin'td
<input type="checkbox"/> <b>methylprednisolone sodium succinate (PF) (SOLU-Medrol) injection 40 mg</b> 40 mg, Intravenous, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting when released, For 1 dose To be administered along with H1 antihistamine and famotidine	PRN		Until discontin'td
<input type="checkbox"/> <b>famotidine (PEPCID) injection 20 mg in sodium chloride 0.9% 100 mL IVPB</b> 20 mg, Intravenous, Administer over 15 Minutes, at 400 mL/hr, Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting when released, For 1 dose. To be administered along with H1 antihistamine and methylprednisolone. HOLD IF: given as a premed.	PRN		Until discontin'td
<input type="checkbox"/> <b>ondansetron (PF) (ZOFTRAN) Injection 4 mg</b> 4 mg, Intravenous, As needed, nausea, vomiting, may repeat x 1 dose, Starting when released, For 2 doses	PRN		Until discontin'td
<input type="checkbox"/> <b>cetirizine (Zyrtec) tablet 10 mg</b> 10 mg, Oral Once as needed, Adjunct treatment for mild-moderate, or SEVERE reaction, Starting at treatment start time, For 1 dose. If patient unable to tolerate cetirizine, administer fexofenadine if available. HOLD IF: given fexofenadine	PRN		Until discontin'td
<input type="checkbox"/> <b>fexofenadine (ALLEGRA) tablet 180 mg</b> 180 mg, Oral, Once as needed, Adjunct treatment for mild-moderated, or SEVERE reaction, Starting at treatment start time, For 1 dose. Administer only if unable to tolerate cetirizine. HOLD IF: given cetirizine	PRN		Until discontin'td